Quetiapine Tablet, Extended Release
Product Images NDC 43547-022

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Quetiapine (NDC 43547-022). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Solco Healthcare U.s., Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Image 01)

Chemical structure diagram showing the molecular formula of quetiapine fumarate, the active ingredient in QUETIAPINE extended-release tablets by Solco Healthcare U.S., LLC. The image depicts the quetiapine molecule and the fumarate salt portion.*

FDA Label Image

Figure 1 (Image 02)

A line graph showing the proportion of patients with relapse (%) over time (months) for two groups labeled PLA and QTP XR. The x-axis represents time in months from 0 to 7, and the y-axis represents the proportion of patients with relapse from 0% to 100%. The PLA group shows a higher and steadily increasing relapse rate, while the QTP XR group shows a lower relapse rate over the same period.*

FDA Label Image

Figure 2 (Image 03)

A line graph depicting the proportion of patients with relapse over time in weeks, comparing two treatment groups: QTP+LI/VAL (quetiapine plus lithium/valproate) and PLA+LI/VAL (placebo plus lithium/valproate). The y-axis shows the proportion of patients with relapse as a percentage, and the x-axis shows time in weeks up to 100 weeks.*

FDA Label Image

Figure 3 (Image 04)

A line graph depicting the proportion of patients with relapse (%) over time in weeks, comparing two treatment groups: QTP + LI/VAL (quetiapine plus lithium/valproate) and PLA + LI/VAL (placebo plus lithium/valproate). The QTP + LI/VAL group shows a lower proportion of relapse over up to 100 weeks compared to the PLA + LI/VAL group.*

FDA Label Image

50 mg 60 Tablets (Image 05)

Label for Quetiapine Extended-Release Tablets, USP 50 mg strength, taken once daily. The oral tablet is distributed by Solco Healthcare U.S., LLC. The label includes storage instructions, a warning to keep out of reach of children, and a barcode. It also states that the product contains 57.56 mg of quetiapine fumarate equivalent to 50 mg quetiapine and comes in a package of 60 tablets.*

FDA Label Image

150 mg 60 Tablets (Image 06)

Label for Quetiapine Extended-Release Tablets, USP 150 mg, oral extended-release tablets by Solco Healthcare U.S., LLC. The label includes dosing information to swallow whole once daily, storage instructions, a warning about medication safety, and manufacturer details (Zhejiang Huahai Pharmaceutical Co., Ltd., China). The package contains 60 tablets.*

FDA Label Image

200 mg 60 Tablets (Image 07)

Quetiapine Extended-Release Tablets USP 200 mg oral tablets in a 60-tablet package. The label states once daily dosing and provides warnings including storage instructions and to keep out of reach of children. Manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd and distributed by Solco Healthcare U.S., LLC.*

FDA Label Image

300 mg 60 Tablets (Image 08)

Quetiapine Extended-Release Tablets USP 300 mg dosage form is shown on a blue and white label. The label states 'Once Daily' administration and contains 60 tablets. It is manufactured by Zhejiang Huahai Pharmaceutical Co., Ltd., China, and distributed by Solco Healthcare U.S., LLC, Somerset, NJ. The label includes storage instructions and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.